PGNY
Strong BuyPremium GrowerAI neutralProgyny, Inc. · Healthcare · United States · $2.2B cap · $30.2M/day traded
$29.06 -1.2% · close 3 Nov · scored 4 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 5 Nov: the next-year EPS estimate has risen 2.9% over the last 13 weeks.
As of 4 Nov 2026, MoatMap's StockRank for Progyny, Inc. (PGNY) is 94/100, ranked against 24,000+ stocks in 35 markets (Quality 78, Value 46, Momentum 76, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
Progyny delivers specialized fertility benefits management to corporate employers, retaining high return on capital and solid balance sheet fundamentals. While share repurchases remain active, recent officer share disposals introduce an element of near-term caution against an increasingly competitive corporate benefits landscape.
ABOUT PROGYNY, INC.
Read
Progyny, Inc. is a leading fertility and family building benefits management company, providing comprehensive and inclusive fertility solutions to large self-insured employers. The company's unique 'Smart Cycle' model and high success rates offer a differentiated value proposition, driving strong employer adoption and member satisfaction. This innovative approach and clinical expertise create a significant competitive moat in the niche but growing market for fertility benefits.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 786.9M | 1.1B | 1.2B | 1.3B | 17.9% | 1.3B | 1.4B | 1.5B | 8.4% |
| EPS | 0.33 | 0.65 | 0.59 | 0.68 | 27.3% | 0.92 | 0.75 | 0.83 | 10.6% |
| Shares | 93.3M | 96.3M | 85.3M | 83.4M | -10.6% | 76.7M | — | — | — |
| Debt | 7.7M | 19.4M | 19.3M | 27.7M | 53.2% | 27.0M | — | — | — |
| Equity | 377.0M | 553.4M | 422.1M | 516.0M | 11.0% | — | — | — | — |
| Op CF | 80.4M | 188.8M | 179.1M | 210.2M | 37.8% | 201.2M | — | — | — |
| Inv CF | -43.9M | -200.5M | 195.8M | -159.0M | — | — | — | — | — |
| Fin CF | -7.9M | -11.1M | -309.9M | -99.4M | — | — | — | — | — |
Above its 200-day average and 12% below its 52-week high.
Swung more than 68% of stocks we rank over the past year (volatility 54% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PGNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PGNY | Progyny, Inc.(you) | $2.2B | 94 | Strong Buy |
| CLOV | Clover Health Investments, Corp. | $2.4B | 75 | Buy |
| OSCR | Oscar Health, Inc. | $9.6B | 99 | Strong Buy |
| CNC | Centene Corporation | $34.7B | 94 | Strong Buy |
| ALHC | Alignment Healthcare, Inc. | $1.7B | 41 | Hold |
| HUM | Humana Inc. | $50.7B | 88 | Strong Buy |
| CI | The Cigna Group | $81.1B | 93 | Strong Buy |
| ELV | Elevance Health, Inc. | $95.4B | 93 | Strong Buy |
| MOH | Molina Healthcare, Inc. | $10.9B | 49 | Hold |
| CVS | CVS Health Corporation | $119.5B | 92 | Strong Buy |
Peer medians: ROE -30.1% · P/E 27.0x · Gross margin 63.4%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.